Previous evidence indicated that suppression of CXCR4 promotes anti-PD-1/PD-L1 efficacy by reshaping the TME in hepatocellular carcinoma (Chen et al., 2015). The gene discussed is CXCR4; the disease is hepatocellular carcinoma.